Literature DB >> 7947387

Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin.

F A Fornari1, W D Jarvis, S Grant, M S Orr, J K Randolph, F K White, V R Mumaw, E T Lovings, R H Freeman, D A Gewirtz.   

Abstract

The effects on DNA integrity of continuous (72-h) exposure of human MCF-7 breast adenocarcinoma cells to 50 nM doxorubicin (a concentration which can be maintained in the plasma by continuous infusion) were characterized by bisbenzimide spectrofluorophotometry, cell flow cytometry, agarose gel electrophoresis, and neutral elution. Spectrofluorophotometry and cell flow cytometry indicated the presence of DNA fragmentation, which was maximal at 24 h. Resolution of these fragments on agarose gels failed to demonstrate "laddered" oligosomal profiles. Neutral elution analysis at 24 h indicated that doxorubicin induced fragmentation of nascent, but not mature, double-stranded DNA. Drug-treated cells exhibited endoreduplication and significant shifts in cell cycle distribution, (i.e., increased G0/G1 and G2/M fractions and a markedly reduced S-phase fraction). These alterations occurred without inhibiting the incorporation of [3H]dThd into cellular DNA; in fact, both the rate and magnitude of [3H]dThd incorporation increased progressively. Doxorubicin also produced a sustained decline in c-myc mRNA levels that paralleled both growth arrest and induction of DNA fragmentation. Ultrastructural examination revealed morphological alterations consistent with the induction of differentiation (e.g., increased lipid content and mitochondrial density, appearance of tight junctions, and secretory ducts) and further suggested the possibility of autocatalysis (e.g., lipofuschin-containing vacuoles). A gradual decline in cell number was observed, with loss of approximately 35% of the cell population after 72 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947387

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  15 in total

1.  Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Linda M McManus; Beth A Goins
Journal:  Cancer Biother Radiopharm       Date:  2011-08-11       Impact factor: 3.099

2.  Kinetics of the cell biological changes occurring in the progression of DNA damage-induced senescence.

Authors:  Sohee Cho; Jihoon Park; Eun Seong Hwang
Journal:  Mol Cells       Date:  2011-04-21       Impact factor: 5.034

3.  Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.

Authors:  Anuradha Soundararajan; Gerald D Dodd; Ande Bao; William T Phillips; Linda M McManus; Thomas J Prihoda; Beth A Goins
Journal:  Radiology       Date:  2011-10-24       Impact factor: 11.105

4.  Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicin.

Authors:  Xiaoli Dong; Lei Xiong; Xinning Jiang; Yinsheng Wang
Journal:  J Proteome Res       Date:  2010-09-23       Impact factor: 4.466

5.  Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.

Authors:  M Koutsilieris; C Reyes-Moreno; I Choki; A Sourla; C Doillon; N Pavlidis
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

6.  Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.

Authors:  Peter Bober; Michal Alexovic; Ivan Talian; Zuzana Tomkova; Zuzana Viscorova; Maria Benckova; Igor Andrasina; Rachele Ciccocioppo; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak; Jan Sabo
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

7.  Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

Authors:  Shai J White; Laura M Kasman; Margaret M Kelly; Ping Lu; Laura Spruill; Paul J McDermott; Christina Voelkel-Johnson
Journal:  Free Radic Biol Med       Date:  2007-07-03       Impact factor: 7.376

8.  Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.

Authors:  Archita Ghoshal; Siddhartha Sankar Ghosh
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

9.  Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison.

Authors:  Christopher R Arthur; John T Gupton; Glen E Kellogg; W Andrew Yeudall; Myles C Cabot; Irene F Newsham; David A Gewirtz
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

10.  Promotion of DNA strand breaks, interstrand cross-links and apoptotic cell death in A2780 human ovarian cancer cells by transplatinum planar amine complexes.

Authors:  Sheena M Aris; David A Gewirtz; John J Ryan; Kenneth M Knott; Nicholas P Farrell
Journal:  Biochem Pharmacol       Date:  2007-02-28       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.